Oramed Pharmaceuticals (ORMP) Income from Continuing Operations (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Income from Continuing Operations came in at 38310000.0 in Q1 2026, up 601.31% YoY from 5462645.45 in Q1 2025, and up 80.75% on a QoQ basis from 21195000.0 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 15 years of Income from Continuing Operations data on file, last reported at 38310000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 601.31% year-over-year to 38310000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 121154000.0 (up 528.42% YoY) and the FY2025 annual result came in at 75202000.0, up 493.67% from the prior year.
- Income from Continuing Operations climbed to 38310000.0 in Q1 2026, from 21195000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 48389000.0 in Q3 2025 to a low of 19642000.0 in Q3 2024.
- A 5-year average of 3319058.82 and a median of 3284000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 800.99% — and 2025, when it slumped 598.17%.
- Tracing ORMP's Income from Continuing Operations over 5 years: stood at 12055000.0 in 2022, then soared by 210.29% to 13296000.0 in 2023, then slumped by 176.71% to 10199000.0 in 2024, then soared by 307.81% to 21195000.0 in 2025, then surged by 80.75% to 38310000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 38310000.0 (Q1 2026), 21195000.0 (Q4 2025), and 48389000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | 78.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.16 Mn |
| Mar 31, 2026 | 38.31 Mn |
| Dec 31, 2025 | 21.20 Mn |
| Sep 30, 2025 | 48.39 Mn |
| Jun 30, 2025 | 13.26 Mn |
| Mar 31, 2025 | -7.64 Mn |
| Dec 31, 2024 | -10.20 Mn |
| Sep 30, 2024 | -19.64 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 13.30 Mn |
| Sep 30, 2023 | -3.28 Mn |
| Jun 30, 2023 | -1.31 Mn |
| Mar 31, 2023 | -3.62 Mn |
| Dec 31, 2022 | -12.06 Mn |
| Sep 30, 2022 | -7.25 Mn |
| Jun 30, 2022 | -12.10 Mn |
| Mar 31, 2022 | -11.65 Mn |
| Aug 31, 2021 | -22.99 Mn |
| Nov 30, 2019 | -2.45 Mn |